Access is no longer decided only in clinics.
This week, it is being decided in Westminster debates, FDA evidence decisions, HIV prevention budgets, vaccine advisory rooms, trade investigations, pharmacy shelves, research labs and in the hidden machinery that determines whether innovation ever reaches a patient.
The question is getting harder.
When prevention exists, who pays to deliver it?
When drug prices become trade policy, who absorbs the shock?
When a patient has no time left, who carries the risk of waiting?
| This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action. |
The swimmer who turned rare brain cancer into a policy fight
Archie Goodburn is not asking for sympathy. He is asking for a system that moves faster than his cancer.
The 24-year-old Scottish swimmer has a rare, inoperable brain cancer, oligodendroglioma. A breakthrough treatment, vorasidenib, helped delay chemotherapy and radiotherapy, giving him time to keep training, studying chemical engineering and preparing for the Commonwealth Games. But his point is sharper than one drug and one patient. One new treatment in 20 years is not a strategy. It is a warning flare. (The Guardian.)
Goodburn and the Brain Cancer Justice campaign are pushing for the UK to release pledged brain cancer research funding, appoint a national brain cancer lead, expand genomic sequencing at diagnosis, improve access to trials and create a stronger “right to try” route for patients who cannot wait politely for the system to catch up. Brain cancer is reported as the biggest cancer killer of people under 40 in the UK, yet it has received only a small fraction of national cancer research funding. (The Guardian.)
This is what personalised medicine looks like when the stakes are human. Genomic sequencing is not a research luxury. It can decide whether a patient is matched to a trial. Expanded access is not a slogan. It can decide whether a young person keeps studying, competing and living with time still on the clock.
A breakthrough drug can buy one patient time. A serious system gives thousands a chance.
IPM Latest
Money and power
The EU budget fight is becoming an access fight
The battle over the EU’s next seven-year budget is no longer a Brussels process story. It is becoming a delivery story.
EU leaders are now openly divided over the proposed 2028–2034 Multiannual Financial Framework, with net contributor countries pushing for significant cuts and others warning against weakening cohesion, agriculture and investment capacity. A compromise that would trim only a small share from the proposed budget has already left several capitals dissatisfied. (Reuters.)
For personalised medicine, this matters because the EU budget is not abstract. It helps determine the scale of investment in research, digital infrastructure, competitiveness, health resilience, skills, regional capacity and cross-border cooperation. These are not side issues. They are the foundations that decide whether precision medicine remains concentrated in a few advanced centres or becomes part of routine care across countries and regions.
The access question is therefore bigger than the size of the budget.
It is whether Europe’s next financial framework will fund the last mile: diagnostics, data systems, implementation capacity, regional networks and equitable patient access.
From Geneva to the G7: cancer and precision medicine move onto the political calendar
The G7 Leaders’ Call on the fight against cancer is a powerful signal that cancer policy is moving beyond rhetoric and back into delivery: prevention, screening, diagnosis, care, research collaboration and faster translation of innovation into health systems. It comes only weeks after the World Health Assembly endorsed a resolution on precision medicine as a path toward targeted, personalised and equitable care. (G7 Évian 2026; WHO.)
For IPM Alliance, this is the political opening we have been building toward. Following our launch activity during the World Health Assembly, IPM is continuing the same delivery conversation with partners across upcoming work in Brazil, China, Ireland and other regional settings. The question is no longer whether precision medicine belongs on the policy agenda. It does.
This is where the Alliance brings added value: through its regional federated network, its ability to connect implementation realities across countries, and the impactful legacy of EAPM in building trusted bridges between science, patients, health systems and policymakers. That bridge now matters more than ever, because political commitments only become meaningful when they are translated into diagnostics, data, referral pathways, reimbursement decisions and equitable patient access.
The next question is harder: can countries turn political ambition into delivery? That is where the last mile begins. This is where IPM will be.
Trade signal
Europe’s China debate is becoming a health-systems issue
EU leaders have given the Commission political space to sharpen Europe’s response to unfair Chinese trade practices, subsidised low-cost imports and strategic dependency. The debate is no longer only about cars, steel or industrial competitiveness. It is about resilience. (Reuters.)
At first glance, this looks like an industrial policy story. But for health systems, the implications go further. Modern personalised medicine depends on secure access to diagnostics, devices, digital tools, laboratory infrastructure, raw materials and resilient supply chains. When trade policy shifts, health systems can feel the shock through procurement, pricing, availability and strategic dependency. (Reuters.)
The lesson is clear: access is no longer shaped only by clinical evidence or reimbursement decisions. It is also shaped by industrial resilience.
The evidence dilemma
When the disease is fatal, how much evidence is enough?
The FDA’s shift on uniQure’s Huntington’s disease gene therapy is one of the most important rare-disease signals of the week.
uniQure says the FDA will now accept existing clinical data to support an accelerated approval application for AMT-130, its investigational gene therapy for Huntington’s disease. Reuters reported that this reverses an earlier FDA position that the data were inadequate, and follows controversy around the idea of a new trial involving sham brain surgery. uniQure plans to submit in the third quarter of 2026. (Reuters.)
This is not a simple “FDA gets flexible” story. It is more uncomfortable than that.
Huntington’s is fatal. There is no approved treatment that slows disease progression. Patients lose time while evidence systems debate what counts as enough. But lowering uncertainty too far creates another risk: approving treatments before benefits and harms are understood well enough.
Rare disease is forcing regulators into the hardest part of personalised medicine: evidence under urgency.
Patients do not have infinite time for perfect evidence. Regulators do not have permission to gamble blindly.
The HIV prevention paradox: breakthrough drug, broken delivery
HIV prevention should be entering a golden moment. Long-acting prevention is becoming real. Lenacapavir is moving into access discussions and rollout plans.
UNAIDS warned that funding cuts have driven a sharp drop in HIV prevention services. Reuters reported that the number of people receiving PrEP fell by 38%, from 3.3 million in 2024 to 2.1 million across 62 countries, while HIV testing also declined in high-burden countries. That is not a small service disruption. That is a prevention infrastructure alarm. (Reuters.)
At the same time, South Africa has begun moving toward access to long-acting lenacapavir for HIV prevention, with Gilead, the Global Fund and government partners involved in the launch effort. That is progress, but it also exposes the tension: a breakthrough can arrive while the system around it is losing staff, money, community reach and trust. (Gilead; AP.)
A prevention product is not a prevention strategy.
The system is the strategy.
Public fights, private stakes
mRNA wants out of the COVID box
Moderna’s mRNA flu vaccine has cleared a major advisory hurdle in the United States. FDA advisers unanimously backed the vaccine for adults aged 50 and older, putting it on track to potentially become the first mRNA seasonal flu shot in the U.S., with an FDA decision expected by early August. (Reuters.)
That sounds like a clean innovation story. It is not.
mRNA is trying to become routine public-health infrastructure after years of being politically branded by the COVID era. The science may move quickly, but vaccine confidence, seasonal contracting, procurement windows and public messaging move on a different clock. Reuters noted that meaningful revenue may not arrive until late 2027 because the vaccine missed key contracting windows. (Reuters.)
This is the private stake behind the public fight: a platform can be scientifically ready and commercially late; clinically promising and politically loaded; approved in principle and still delayed in practice.
The future of prevention will not be won by the platform alone.
It will be won by trust, timing and delivery.
Patient access
Sometimes access means being on the shelf
Not every access story involves genomics, AI or a billion-dollar therapy.
The FDA approved Rextovy, another over-the-counter naloxone nasal spray for emergency treatment of opioid overdose. Naloxone rapidly reverses opioid overdose, and making more formulations available without prescription can expand access, support competition and improve sourcing options. (FDA.)
This is access in its most practical form.
No complex pathway. No molecular board. No prestige congress. Just a product that needs to be reachable when a life is at risk.
The best emergency medicine is the one someone can actually get.
The June watchlist
June is not done. The second half of the month brings decisions and meetings that could shape the next access fights.
| 19 June, EU & online: |
| European Commission HTA webinar for high-risk medical devices and IVD developers. |
| 22 June, UK: |
| The MHRA consultation on gene therapy regulation closes. (MHRA.) |
| 22-25 June, Amsterdam: |
| EMA committee for medicinal products for human use plenary. |
| 22-25 June, San Diego, US: |
| BIO International Convention gathers the biotech ecosystem. (BIO.) |
| 24-27 June, Philadelphia, US: |
| AACR’s malignant lymphoma meeting puts blood cancers back in the precision medicine spotlight. (AACR.) |
Follow the last-mile conversation!
IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.
We want to hear from you
When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?
Know someone who should be reading this?
IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.
International Alliance for Personalised Medicine
Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium
This email was sent to jayasinghtec29@gmail.com. You are receiving this email because you are part of the IPM Alliance network or have engaged with our activities, briefings, events, or policy work.
